Literature DB >> 19225547

Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.

T Nishimoto1, K Yoshida, Y Miura, A Kobayashi, H Hara, S Ohnami, K Kurisu, T Yoshida, K Aoki.   

Abstract

A conditionally replicative adenovirus is a novel anticancer agent designed to replicate selectively in tumor cells. However, a leak of the virus into systemic circulation from the tumors often causes ectopic infection of various organs. Therefore, suppression of naive viral tropism and addition of tumor-targeting potential are necessary to secure patient safety and increase the therapeutic effect of an oncolytic adenovirus in the clinical setting. We have recently developed a direct selection method of targeted vector from a random peptide library displayed on an adenoviral fiber knob to overcome the limitation that many cell type-specific ligands for targeted adenovirus vectors are not known. Here we examined whether the addition of a tumor-targeting ligand to a replication-competent adenovirus ablated for naive tropism enhances its therapeutic index. First, a peptide-display adenovirus library was screened on a pancreatic cancer cell line (AsPC-1), and particular peptide sequences were selected. The replication-competent adenovirus displaying the selected ligand (AdDeltaCAR-SYE) showed higher oncolytic potency in several other pancreatic cancer cell lines as well as AsPC-1 compared with the untargeted adenovirus (AdDeltaCAR). An intratumoral injection of AdDeltaCAR-SYE significantly suppressed the growth of AsPC-1 subcutaneous tumors, and an analysis of adenovirus titer in the tumors revealed an effective replication of the virus in the tumors. Ectopic liver gene transduction following the intratumoral injection of AdDeltaCAR-SYE was not increased compared with the AdDeltaCAR. The results showed that a tumor-targeting strategy using an adenovirus library is promising for optimizing the safety and efficacy of oncolytic adenovirus therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225547     DOI: 10.1038/gt.2009.1

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  23 in total

Review 1.  Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

Authors:  Christoforos Kosmidis; Konstantinos Sapalidis; Efstathios Kotidis; Nikolaos Mixalopoulos; Paul Zarogoulidis; Drosos Tsavlis; Sofia Baka; Yan-Gao Man; John Kanellos
Journal:  Ann Transl Med       Date:  2016-05

Review 2.  Oncolytic virotherapy for pancreatic cancer.

Authors:  Sonia Wennier; Shoudong Li; Grant McFadden
Journal:  Expert Rev Mol Med       Date:  2011-05-18       Impact factor: 5.600

3.  Novel therapies for pancreatic cancer: setbacks and progress.

Authors:  Han Hsi Wong; Nicholas R Lemoine
Journal:  Future Oncol       Date:  2010-07       Impact factor: 3.404

4.  Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library.

Authors:  Yoshiaki Miura; Satoshi Yamasaki; Julia Davydova; Eric Brown; Kazunori Aoki; Selwyn Vickers; Masato Yamamoto
Journal:  Mol Ther       Date:  2012-10-02       Impact factor: 11.454

Review 5.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

6.  Development of a novel efficient method to construct an adenovirus library displaying random peptides on the fiber knob.

Authors:  Yuki Yamamoto; Naoko Goto; Kazuki Miura; Kenta Narumi; Shumpei Ohnami; Hiroaki Uchida; Yoshiaki Miura; Masato Yamamoto; Kazunori Aoki
Journal:  Mol Pharm       Date:  2014-01-24       Impact factor: 4.939

7.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

Review 8.  Viro-immune therapy: A new strategy for treatment of pancreatic cancer.

Authors:  Andrea Marie Ibrahim; Yao-He Wang
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 9.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

10.  Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.

Authors:  Quyen D Chu; Guang Sun; Matt Pope; Natalia Luraguiz; David T Curiel; Roger Kim; Benjamin D L Li; J Michael Mathis
Journal:  Surgery       Date:  2012-07-31       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.